Which has preferable earnings and valuation, SLP or AZTA?

Azenta has higher revenue and earnings than Simulations Plus. Azenta is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Simulations Plus $79.18M 4.71 -$64.72M $0.40 46.10 Azenta $593.82M 2.45 -$55.76M -$2.76 N/A

Is SLP or AZTA more profitable?

Simulations Plus has a net margin of 9.88% compared to Azenta's net margin of -20.63%. Simulations Plus' return on equity of 13.50% beat Azenta's return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% Azenta -20.63% 1.18% 0.97%

Does the media refer more to SLP or AZTA?

In the previous week, Azenta had 5 more articles in the media than Simulations Plus. MarketBeat recorded 8 mentions for Azenta and 3 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.53 beat Azenta's score of 0.39 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Azenta 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, CYRX or SLP?

CryoPort has higher revenue and earnings than Simulations Plus. CryoPort is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.89 $78.30M -$0.90 N/A Simulations Plus $79.18M 4.71 -$64.72M $0.40 46.10

Does the media refer more to CYRX or SLP?

In the previous week, CryoPort had 3 more articles in the media than Simulations Plus. MarketBeat recorded 6 mentions for CryoPort and 3 mentions for Simulations Plus. CryoPort's average media sentiment score of 0.95 beat Simulations Plus' score of 0.53 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLAB or SLP?

In the previous week, Simulations Plus had 2 more articles in the media than Mesa Laboratories. MarketBeat recorded 3 mentions for Simulations Plus and 1 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 1.82 beat Simulations Plus' score of 0.53 indicating that Mesa Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CTKB or SLP?

In the previous week, Simulations Plus had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Simulations Plus and 2 mentions for Cytek Biosciences. Simulations Plus' average media sentiment score of 0.53 beat Cytek Biosciences' score of 0.26 indicating that Simulations Plus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, OABI or SLP?

Simulations Plus has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A Simulations Plus $79.18M 4.71 -$64.72M $0.40 46.10

Is OABI or SLP more profitable?

Simulations Plus has a net margin of 9.88% compared to OmniAb's net margin of -115.12%. Simulations Plus' return on equity of 13.50% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -115.12% -16.59% -14.82% Simulations Plus 9.88% 13.50% 12.45%

Does the media prefer OABI or SLP?

In the previous week, Simulations Plus had 1 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for Simulations Plus and 2 mentions for OmniAb. OmniAb's average media sentiment score of 0.60 beat Simulations Plus' score of 0.53 indicating that OmniAb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Simulations Plus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Simulations Plus (SLP) Competitors

$18.44 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$18.44 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Compare

SLP vs. AZTA, CYRX, MLAB, CTKB, and OABI

Should you buy Simulations Plus stock or one of its competitors? Simulations Plus's main competitors and comparable companies include Azenta (AZTA), CryoPort (CYRX), Mesa Laboratories (MLAB), Cytek Biosciences (CTKB), and OmniAb (OABI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Simulations Plus compare to Azenta?

Simulations Plus (NASDAQ:SLP) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

In the previous week, Azenta had 5 more articles in the media than Simulations Plus. MarketBeat recorded 8 mentions for Azenta and 3 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 0.53 beat Azenta's score of 0.39 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Azenta	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Azenta has higher revenue and earnings than Simulations Plus. Azenta is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$79.18M	4.71	-$64.72M	$0.40	46.10
Azenta	$593.82M	2.45	-$55.76M	-$2.76	N/A

Simulations Plus has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Azenta has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 19.1% of Simulations Plus shares are held by insiders. Comparatively, 10.9% of Azenta shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Simulations Plus currently has a consensus target price of $17.25, indicating a potential downside of 6.45%. Azenta has a consensus target price of $41.20, indicating a potential upside of 23.95%. Given Azenta's stronger consensus rating and higher probable upside, analysts clearly believe Azenta is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Simulations Plus has a net margin of 9.88% compared to Azenta's net margin of -20.63%. Simulations Plus' return on equity of 13.50% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Azenta	-20.63%	1.18%	0.97%

Summary

Simulations Plus and Azenta tied by winning 8 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

In the previous week, CryoPort had 3 more articles in the media than Simulations Plus. MarketBeat recorded 6 mentions for CryoPort and 3 mentions for Simulations Plus. CryoPort's average media sentiment score of 0.95 beat Simulations Plus' score of 0.53 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort presently has a consensus price target of $18.00, indicating a potential upside of 5.76%. Simulations Plus has a consensus price target of $17.25, indicating a potential downside of 6.45%. Given CryoPort's stronger consensus rating and higher possible upside, equities analysts clearly believe CryoPort is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

CryoPort has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

92.9% of CryoPort shares are held by institutional investors. Comparatively, 78.1% of Simulations Plus shares are held by institutional investors. 9.5% of CryoPort shares are held by company insiders. Comparatively, 19.1% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CryoPort has higher revenue and earnings than Simulations Plus. CryoPort is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.89	$78.30M	-$0.90	N/A
Simulations Plus	$79.18M	4.71	-$64.72M	$0.40	46.10

Simulations Plus has a net margin of 9.88% compared to CryoPort's net margin of -20.05%. Simulations Plus' return on equity of 13.50% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Simulations Plus	9.88%	13.50%	12.45%

Summary

CryoPort beats Simulations Plus on 10 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to Mesa Laboratories?

Mesa Laboratories (NASDAQ:MLAB) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Mesa Laboratories has higher revenue and earnings than Simulations Plus. Simulations Plus is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.13M	2.84	$6.71M	$0.84	150.64
Simulations Plus	$79.18M	4.71	-$64.72M	$0.40	46.10

Simulations Plus has a net margin of 9.88% compared to Mesa Laboratories' net margin of 1.92%. Mesa Laboratories' return on equity of 22.72% beat Simulations Plus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.72%	9.82%
Simulations Plus	9.88%	13.50%	12.45%

90.6% of Mesa Laboratories shares are owned by institutional investors. Comparatively, 78.1% of Simulations Plus shares are owned by institutional investors. 2.8% of Mesa Laboratories shares are owned by company insiders. Comparatively, 19.1% of Simulations Plus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mesa Laboratories has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market.

Mesa Laboratories presently has a consensus price target of $110.00, suggesting a potential downside of 13.07%. Simulations Plus has a consensus price target of $17.25, suggesting a potential downside of 6.45%. Given Simulations Plus' higher possible upside, analysts plainly believe Simulations Plus is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

In the previous week, Simulations Plus had 2 more articles in the media than Mesa Laboratories. MarketBeat recorded 3 mentions for Simulations Plus and 1 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 1.82 beat Simulations Plus' score of 0.53 indicating that Mesa Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mesa Laboratories beats Simulations Plus on 8 of the 15 factors compared between the two stocks.

How does Simulations Plus compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Simulations Plus has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.42	-$66.54M	-$0.62	N/A
Simulations Plus	$79.18M	4.71	-$64.72M	$0.40	46.10

Simulations Plus has a net margin of 9.88% compared to Cytek Biosciences' net margin of -38.98%. Simulations Plus' return on equity of 13.50% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Simulations Plus	9.88%	13.50%	12.45%

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 78.1% of Simulations Plus shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Comparatively, 19.1% of Simulations Plus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Simulations Plus had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Simulations Plus and 2 mentions for Cytek Biosciences. Simulations Plus' average media sentiment score of 0.53 beat Cytek Biosciences' score of 0.26 indicating that Simulations Plus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Cytek Biosciences presently has a consensus price target of $5.56, suggesting a potential upside of 4.95%. Simulations Plus has a consensus price target of $17.25, suggesting a potential downside of 6.45%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cytek Biosciences is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

Summary

Simulations Plus beats Cytek Biosciences on 12 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to OmniAb?

OmniAb (NASDAQ:OABI) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Simulations Plus had 1 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for Simulations Plus and 2 mentions for OmniAb. OmniAb's average media sentiment score of 0.60 beat Simulations Plus' score of 0.53 indicating that OmniAb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Simulations Plus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OmniAb has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Simulations Plus has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A
Simulations Plus	$79.18M	4.71	-$64.72M	$0.40	46.10

Simulations Plus has a net margin of 9.88% compared to OmniAb's net margin of -115.12%. Simulations Plus' return on equity of 13.50% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Simulations Plus	9.88%	13.50%	12.45%

OmniAb presently has a consensus target price of $11.00, suggesting a potential upside of 146.09%. Simulations Plus has a consensus target price of $17.25, suggesting a potential downside of 6.45%. Given OmniAb's stronger consensus rating and higher possible upside, equities analysts plainly believe OmniAb is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

72.1% of OmniAb shares are held by institutional investors. Comparatively, 78.1% of Simulations Plus shares are held by institutional investors. 9.8% of OmniAb shares are held by company insiders. Comparatively, 19.1% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Simulations Plus beats OmniAb on 11 of the 16 factors compared between the two stocks.

Get Simulations Plus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLP vs. The Competition

Export

Metric	Simulations Plus	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$372.95M	$10.40B	$7.24B	$13.19B
Dividend Yield	N/A	1.46%	2.57%	12.81%
P/E Ratio	46.10	70.70	275.49	25.40
Price / Sales	4.71	108.53	646.01	89.45
Price / Cash	12.88	27.47	76.25	51.42
Price / Book	2.97	5.70	10.46	6.33
Net Income	-$64.72M	$56.67B	$3.49B	$358.33M
7 Day Performance	0.11%	4.59%	0.59%	1.12%
1 Month Performance	0.33%	0.07%	-1.74%	-2.39%
1 Year Performance	20.92%	27.93%	18.13%	5.35%

Simulations Plus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLP Simulations Plus	0.6107 of 5 stars	$18.44 flat	$17.25 -6.5%	+20.9%	$372.95M	$79.18M	46.10	213	News Coverage
AZTA Azenta	2.4251 of 5 stars	$33.13 +3.4%	$41.20 +24.4%	+6.9%	$1.46B	$613.81M	N/A	3,000
CYRX CryoPort	1.8815 of 5 stars	$16.23 +1.7%	$18.00 +10.9%	+70.7%	$823.06M	$176.18M	N/A	738	News Coverage Positive News Analyst Forecast
MLAB Mesa Laboratories	1.4048 of 5 stars	$123.88 +2.0%	$110.00 -11.2%	+73.0%	$692.31M	$249.13M	147.18	717
CTKB Cytek Biosciences	1.2725 of 5 stars	$4.94 +2.2%	$5.56 +12.7%	+40.2%	$642.77M	$206.71M	N/A	702	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLP) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Simulations Plus (SLP) Competitors

SLP vs. AZTA, CYRX, MLAB, CTKB, and OABI

How does Simulations Plus compare to Azenta?

Summary

How does Simulations Plus compare to CryoPort?

Summary

How does Simulations Plus compare to Mesa Laboratories?

Summary

How does Simulations Plus compare to Cytek Biosciences?

Summary

How does Simulations Plus compare to OmniAb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLP vs. The Competition

Simulations Plus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Simulations Plus (SLP) Competitors

SLP vs. AZTA, CYRX, MLAB, CTKB, and OABI

How does Simulations Plus compare to Azenta?

Does the media refer more to SLP or AZTA?

Which has preferable earnings and valuation, SLP or AZTA?

Which has more volatility & risk, SLP or AZTA?

Do insiders and institutionals believe in SLP or AZTA?

Do analysts prefer SLP or AZTA?

Is SLP or AZTA more profitable?

Summary

How does Simulations Plus compare to CryoPort?

Does the media refer more to CYRX or SLP?

Do analysts prefer CYRX or SLP?

Which has more volatility and risk, CYRX or SLP?

Do insiders & institutionals believe in CYRX or SLP?

Which has better valuation and earnings, CYRX or SLP?

Is CYRX or SLP more profitable?

Summary

How does Simulations Plus compare to Mesa Laboratories?

Which has higher valuation and earnings, MLAB or SLP?

Is MLAB or SLP more profitable?

Do insiders and institutionals hold more shares of MLAB or SLP?

Which has more volatility & risk, MLAB or SLP?

Do analysts prefer MLAB or SLP?

Does the media refer more to MLAB or SLP?

Summary

How does Simulations Plus compare to Cytek Biosciences?

Which has stronger valuation and earnings, CTKB or SLP?

Is CTKB or SLP more profitable?

Do institutionals and insiders have more ownership in CTKB or SLP?

Does the media refer more to CTKB or SLP?

Which has more risk and volatility, CTKB or SLP?

Do analysts recommend CTKB or SLP?

Summary

How does Simulations Plus compare to OmniAb?

Does the media prefer OABI or SLP?

Which has more volatility & risk, OABI or SLP?

Which has higher earnings and valuation, OABI or SLP?

Is OABI or SLP more profitable?

Do analysts rate OABI or SLP?

Do institutionals & insiders hold more shares of OABI or SLP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLP vs. The Competition

Simulations Plus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools